Transforming Personalized Medicine into Off-the-Shelf Cell Therapies
Initial progress in cell and gene therapy has seen 12 advanced therapeutic medicinal products (ATMPs) become available on the market in 2019 for a range of conditions, from monogenic diseases to cancer. Despite major progress in the commercialization of ATMPs, the development of these treatments presents manufacturability challenges and questions about bypassing patients’ immune systems.
The availability of rapid sequencing and next-generation bioinformatics has made it possible to understand the mechanisms of disease better and accelerate the development of therapeutic responses. How can the same toolbox be applied to address these challenges in transforming autologous personalized treatments into allogeneic off-the-shelf cell therapies?View all resources